Celemics’ G-Mendeliome Clinical Exome Sequencing (CES) Panel is
designed to overcome the limitations of analyzing clinical diseases
with conventional whole-exome sequencing.
genetic variations within target genes in the human genome. G-Mendeliome CES panel included clinically significant genes used in various other panels
as well as additional genes, therefore, customers can obtain comprehensive information
of mutations in genes of interest cost-effectively.
- Comprehensive genomic profiling of a variety of genetic diseases
- Includes 7,000 genes associated with clinically significant genetic diseases
- A wide range of target regions
- Includes all clinically significant regions that are not
covered from competitor panels
- Cost-effective analysis
- Able to provide accurate analysis with reduced sequencing
costs compared to WES
Design of G-Mendeliome CES panel and comparison data
G-mendeliome CES :
Company A + Company B + over 70 genes
The CES Panel was developed from the needs of GC Genome,
the largest clinical NGS service Provider in korea,
to solve the problem of poor diagnosis and high costs
Coparison data : ZNF419 gene
Comparison data: COL6A5 gene
By the in-house manufacturing and probe design system of Celemics, customers can request the sequencing of homolog regions as well as hard-to-capture regions.
The comparison data showed obtained sequencing reads for ZNF419 and COL6A5 genes which commonly masked in other panels.
Example of metagenomic sequencing analysis report
G-Mendeliome CES panel contains around 7,000 disease-related genes as target regions. The related diseases are listed in the table below.
Higher uniform read depths over GC-rich regions compared to competitor product
Somatic cancer related fields
Research for Inherited disease